OptiNose (OPTN) Projected to Post Earnings on Tuesday

OptiNose (NASDAQ:OPTN - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect OptiNose to post earnings of ($0.74) per share and revenue of $17.70 million for the quarter.

OptiNose (NASDAQ:OPTN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.67. The company had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million. On average, analysts expect OptiNose to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OptiNose Stock Performance

OPTN stock remained flat at $9.39 during trading on Friday. 8,064 shares of the company were exchanged, compared to its average volume of 59,589. The firm has a market cap of $95.09 million, a P/E ratio of -2.24 and a beta of -0.88. OptiNose has a one year low of $4.82 and a one year high of $20.03. The business has a fifty day simple moving average of $8.39 and a 200-day simple moving average of $7.50.

Insider Transactions at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now directly owns 126,931 shares of the company's stock, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 8,213 shares of company stock worth $43,643 over the last quarter. 2.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

OPTN has been the subject of a number of research analyst reports. HC Wainwright restated a "neutral" rating and issued a $9.00 target price (down previously from $18.00) on shares of OptiNose in a research note on Friday, March 21st. Piper Sandler reaffirmed a "neutral" rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a report on Friday, March 21st. Finally, Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and cut their price target for the stock from $17.00 to $9.00 in a report on Thursday, March 20th.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.